VIAV Form 4: Richard Belluzzo disposes 8,387 shares; 217,154 remain
Rhea-AI Filing Summary
VIAVI Solutions director Richard Belluzzo reported a sale of company stock under a pre-established trading plan. On 10/01/2025 Mr. Belluzzo disposed of 8,387 shares of VIAV common stock under a Rule 10b5-1 trading plan dated February 4, 2025, at a weighted-average price of $12.63 per share. After the reported sale, he beneficially owns 217,154 shares, which include 83,292 shares held in trust for his family for which he has sole voting and investment power. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact.
Positive
- Sale executed under a Rule 10b5-1 plan, indicating pre-specified trading and reduced concern about opportunistic timing.
- Substantial remaining beneficial ownership of 217,154 shares, including 83,292 shares held in trust where the reporting person retains sole voting and investment power.
- Transparent disclosure of weighted-average sale price range ($12.50–$12.73) and undertaking to provide full trade details on request.
Negative
- Insider disposition of 8,387 shares may be viewed negatively by some investors despite use of a trading plan.
- Sale executed at modest prices ($12.50–$12.73), which could be interpreted as partial realization of gains or rebalancing.
Insights
TL;DR: A director sold a modest stake under a Rule 10b5-1 plan; substantial holdings remain.
The reported 8,387-share sale is an executed transaction under a pre-established 10b5-1 plan, reducing Mr. Belluzzo's direct beneficial position to 217,154 shares. The weighted-average sale price of $12.63 reflects multiple trades between $12.50 and $12.73. This disclosure is routine for insiders using trading plans and provides transparency about timing and execution. The remaining position, including 83,292 trust-held shares with sole voting and investment power, indicates continued alignment with shareholder outcomes.
TL;DR: Transaction follows a documented trading plan and was properly disclosed; governance protocols observed.
The Form 4 shows the sale was conducted pursuant to a documented Rule 10b5-1 plan dated February 4, 2025, which helps insulate the director from accusations of opportunistic trading. The filing was made by one reporting person and executed via attorney-in-fact, consistent with common governance practices. The retained holdings and trust arrangement are disclosed, clarifying voting and investment authority and supporting transparency for investors and regulators.